87 related articles for article (PubMed ID: 1806186)
41. Can treatment with the monoclonal antibody BMA031 induce cytokine release?
Zlabinger GJ; Pohanka E; Stuhlmeier KM; Eher R; Schmaldienst S; Watschinger B; Steiner G; Kovarik J
Transplant Proc; 1992 Feb; 24(1):271-2. PubMed ID: 1539278
[No Abstract] [Full Text] [Related]
42. Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2.
Tibben JG; Boerman OC; Claessens RA; Corstens FH; van Deuren M; de Mulder PH; van der Meer JW; Keijser KG; Massuger LF
J Natl Cancer Inst; 1993 Jun; 85(12):1003-4. PubMed ID: 8496973
[No Abstract] [Full Text] [Related]
43. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.
Eastwood D; Bird C; Dilger P; Hockley J; Findlay L; Poole S; Thorpe SJ; Wadhwa M; Thorpe R; Stebbings R
Br J Clin Pharmacol; 2013 Aug; 76(2):299-315. PubMed ID: 23701319
[TBL] [Abstract][Full Text] [Related]
44. Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala).
Ablamunits V; Herold KC
Hum Immunol; 2008 Nov; 69(11):732-6. PubMed ID: 18817833
[TBL] [Abstract][Full Text] [Related]
45. Recombinant chimeric OKT3/IgM antibodies for immune suppression: evaluation in a human CD3 transgenic mouse model.
Choi I; Schmitt WE; Bähre A; Little M; Cochlovius B
Immunol Lett; 2002 Feb; 80(2):125-8. PubMed ID: 11750044
[TBL] [Abstract][Full Text] [Related]
46. Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.
Nouveau L; Buatois V; Cons L; Chatel L; Pontini G; Pleche N; Ferlin WG
Eur J Immunol; 2021 Aug; 51(8):2074-2085. PubMed ID: 33945643
[TBL] [Abstract][Full Text] [Related]
47. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids.
Chatenoud L; Ferran C; Legendre C; Thouard I; Merite S; Reuter A; Gevaert Y; Kreis H; Franchimont P; Bach JF
Transplantation; 1990 Apr; 49(4):697-702. PubMed ID: 2109379
[TBL] [Abstract][Full Text] [Related]
48. Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activation in vitro.
Choi I; De Ines C; Kürschner T; Cochlovius B; Sörensen V; Olafsen T; Sandlie I; Little M
Eur J Immunol; 2001 Jan; 31(1):94-106. PubMed ID: 11169443
[TBL] [Abstract][Full Text] [Related]
49. Development of a flow cytometry-based potency assay for prediction of cytokine storms induced by biosimilar monoclonal antibodies.
Madsen NH; Gad M; Larsen J
J Immunol Methods; 2022 Mar; 502():113231. PubMed ID: 35122772
[TBL] [Abstract][Full Text] [Related]
50. Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype.
Wing MG; Waldmann H; Isaacs J; Compston DA; Hale G
Ther Immunol; 1995 Aug; 2(4):183-90. PubMed ID: 9358610
[TBL] [Abstract][Full Text] [Related]
51. Immunopotentiation of anti-viral and anti-tumor immune responses using anti-T cell receptor antibodies and mitogens.
Newell KA; Ellenhorn JD; Hirsch R; Bluestone JA
Ann N Y Acad Sci; 1991 Dec; 636():279-87. PubMed ID: 1793214
[TBL] [Abstract][Full Text] [Related]
52. Bone marrow-liver-thymus (BLT) immune humanized mice as a model to predict cytokine release syndrome.
Yan H; Semple KM; Gonzaléz CM; Howard KE
Transl Res; 2019 Aug; 210():43-56. PubMed ID: 31082370
[TBL] [Abstract][Full Text] [Related]
53. Anti-CD3 antibodies for type 1 diabetes: beyond expectations.
Bach JF
Lancet; 2011 Aug; 378(9790):459-60. PubMed ID: 21719098
[No Abstract] [Full Text] [Related]
54. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites.
Chatenoud L; Legendre C; Ferran C; Bach JF; Kreis H
Transplantation; 1991 Feb; 51(2):334-8. PubMed ID: 1899732
[TBL] [Abstract][Full Text] [Related]
55. Monoclonal antibody-induced cytokine-release syndrome.
Bugelski PJ; Achuthanandam R; Capocasale RJ; Treacy G; Bouman-Thio E
Expert Rev Clin Immunol; 2009 Sep; 5(5):499-521. PubMed ID: 20477639
[TBL] [Abstract][Full Text] [Related]
56. Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics.
Fletcher EAK; Eltahir M; Lindqvist F; Rieth J; Törnqvist G; Leja-Jarblad J; Mangsbo SM
Int Immunopharmacol; 2018 Jan; 54():1-11. PubMed ID: 29100032
[TBL] [Abstract][Full Text] [Related]
57. Pillars Article: OKT3: A Monoclonal Anti-Human T Lymphocyte Antibody with Potent Mitogenic Properties. J. Immunol. 1980. 124: 2708-2713.
Van Wauwe JP; De Mey JR; Goossens JG
J Immunol; 2016 Nov; 197(9):3431-3436. PubMed ID: 27824589
[No Abstract] [Full Text] [Related]
58. Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies.
Feasby TE
J Neurol Neurosurg Psychiatry; 1991 Jan; 54(1):51-4. PubMed ID: 1901348
[TBL] [Abstract][Full Text] [Related]
59. In vitro cytokine release assays: reducing the risk of adverse events in man.
Kirton CM; Gliddon DR; Bannish G; Bembridge GP; Coney LA
Bioanalysis; 2011 Dec; 3(23):2657-63. PubMed ID: 22136053
[TBL] [Abstract][Full Text] [Related]
60. Analysis of cytokine release assay data using machine learning approaches.
Xiong F; Janko M; Walker M; Makropoulos D; Weinstock D; Kam M; Hrebien L
Int Immunopharmacol; 2014 Oct; 22(2):465-79. PubMed ID: 25107440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
